Results 81 to 90 of about 76,403 (315)
The expression of p53 protein in patients with multiple myeloma
Srpski arhiv za celokupno lekarstvo, 2007 Introduction: Although mutations of p53 are one of the most often acquired genetic changes in malignant tumors, these mutations are rare events in patients with newly diagnosed multiple myeloma (MM). Moreover, there are a few literature data about clinical significance of p53 overexpression in multiple myeloma.
Milica Colovic +4 more
openaire +4 more sources
Advanced Science, EarlyView.Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen +16 more
wiley +1 more source
Haematologica, 2018 Histone deacetylases are promising therapeutic targets in hematological malignancies. In the work herein, we investigated the effect of chidamide, a new subtype-selective histone deacetylase inhibitor that was independently produced in China, on multiple
Jingsong He +14 more
doaj +1 more source
Investigation of urinary proteins in multiple myeloma by means of salting-out analysis [PDF]
, 1955 Elizabeth P. Steyn-Parvé +1 more
openalex +1 more source
Harnessing the Biological Responses Induced by Nanomaterials for Enhanced Cancer Therapy
Aggregate, EarlyView.Nanomaterial (NM)‐induced toxicity can be strategically repurposed for cancer therapy. This review summarizes the mechanism by which NMs selectively activate specific cellular processes to regulate cell fate independently. We also discussed how NMs‐induced biological responses can be leveraged as therapeutic strategies for cancer treatment.
Liting Wang +6 more
wiley +1 more source
DangER: protein ovERload. Targeting protein degradation to treat myeloma
Haematologica, 2012 Myeloma is a malignancy of the antibody-producing plasma cells and, as such, these cells synthesize large quantities of unfolded or misfolded immunoglobulin.
Lauren I. Aronson, Faith E. Davies
doaj +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight ...
Midori Filiz Nishimura +14 more
wiley +1 more source
MULTIPLE MYELOMA. IV. ABNORMAL SERUM COMPONENTS AND BENCE JONES PROTEIN 1 [PDF]
, 1951 R. Wayne Rundles +2 more
openalex +1 more source
American Journal of Hematology, EarlyView.9% of patients with multiple myeloma achieve 15‐year progression‐free survival; Kaplan‐Meier curves for PFS (A) and OS (B). ABSTRACT The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their
Meletios A. Dimopoulos +17 more
wiley +1 more source
FRACTIONATION OF SERUM PROTEINS IN HYPERPROTEINEMIA, WITH SPECIAL REFERENCE TO MULTIPLE MYELOMA [PDF]
, 1941 Alexander B. Gutman +4 more
openalex +1 more source